간편하게 보는 뉴스는 유니콘뉴스
AACR 2024: PDC*line Pharma Presents Interim Clinical Results From Last Cohort of Patients in Phase I/II Trial with PDC*lung01 Cancer Vaccine

· 등록일 Apr. 09, 2024 12:05

· 업데이트일 2024-04-10 00:05:46

LIÈGE, BELGIUM & GRENOBLE, FRANCE--(Business Wire / Korea Newswire)--PDC*line Pharma, a clinical-stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, today announces the interim results from the last cohort of patients in its phase I/II clinical trial (PDC-LUNG-101, NCT03970746) with PDC*lung01.

PDC*lung01 is the company’s off-the shelf therapeutic cancer vaccine candidate for Non-Small Cell Lung Cancer (NSCLC). The preliminary data on the last cohort of patients was presented today through both an oral presentation and a poster at the American Association for Cancer Research (AACR) Annual Meeting 2024. This data revealed that the high dose PDC*lung01 combined with pembrolizumab shows an immunological activity in a majority of patients and a promising antitumor response in stage IV NSCLC with a mild safety profile.

The phase I/II trial (PDC-LUNG-101) aimed to assess the safety, tolerability, immunogenicity and preliminary clinical activity of PDC*lung01 in NSCLC patients, alone or in combination with anti-PD-1 treatment. PDC*lung01 was administered weekly through both subcutaneous and intravenous routes, in six consecutive doses. The trial was conducted across 17 clinical sites in France, Belgium, Germany, the Netherlands and Poland. PDC*lung01 was administered to a total of 67 evaluable HLA-A*02:01 positive NSCLC patients, at two dose levels and settings:

· As a single agent in the adjuvant setting (cohorts A1: Low Dose, A2: High Dose)
· Combined with standard of care anti-PD-1 monotherapy in first-line stage IV (metastatic) NSCLC patients with a PD-L1 tumor proportion score of ≥50% and no targetable driver mutation (cohorts B1: Low Dose, B2: High Dose)

Clinical activity parameters such as Objective Response Rate (ORR) and Progression-Free Survival (PFS) were assessed only in cohorts B1 and B2. The B2 cohort included 45 patients. PDC*Line is reporting preliminary efficacy results for 19 evaluable patients in the B2 cohort that reached the 9-month PFS mark.

Key highlights from the oral presentation
Title: Preliminary clinical results of a therapeutic cancer vaccine PDC*lung01 in combination with anti-PD-1 in patients with Stage IV NSCLC

· PDC*lung01 treatment at high dose with pembrolizumab exhibited a mild safety profile
At database cut-off, 38 patients started treatment. Out of the 21 patients in the B2 cohort who started treatment and reached the 9-month follow-up, 19 received at least 5 doses of PDC*lung01 and had 1 post-baseline radiological evaluation, qualifying them as evaluable per protocol. Overall, the high dose of PDC*lung01 showed an acceptable safety profile. Most of the treatment-related AEs were consistent with AEs associated with SC/IV injections of other vaccines, or with AEs already observed in clinical trials of anti-cancer vaccines. The evaluation of the SAEs reported did not identify any safety concerns.

· PDC*lung01 demonstrated biological activity in triggering an antitumor immune response in the majority of patients
A peptide-specific and effector memory CD8+ T-cell response was induced against the lung antigens of PDC*lung01 in 68.4% of patients. Immune responses with remarkable expanded anti-tumor CD8+ T-cells were observed in both Partial Response and Stable Disease patients. More immune response results will be available in the final analysis of the 45 patients in cohort B2.

· PDC*lung01, in combination with pembrolizumab, is associated with a promising objective response rate and progression free survival in first line setting stage IV NSCLC patients
With the 19 evaluable patients, the median follow-up at the database lock was 12.5 months (95% CI: 9.9, 14.2). The Best Objective Response (BOR) included 12 Partial Response (63.2%) and 7 Stable Disease (36.8%) with ORR of 63.2% (80% CI 45.9 - 78.2) and a Disease Control Rate (DCR) of 94.7% (80% CI: 81, 99.4). The 9-month PFS according to the Kaplan-Meier estimate was 52.1% (80% CI 36.5 - 65.56). The median PFS was 10.9 months (95% CI 5.6 - Not Reached). The median duration of response was 9.49 months (95% CI: 4.4, -).

The safety, immunological and clinical activity results from the B2 cohort are consistent with the data from the first three cohorts of patients (A1, A2 and B1) that were presented at ESMO 2022 in September 2022 in Paris (France) and ESMO-IO in December 2022 in Geneva (Switzerland).

The final analysis of the clinical trial including the 45 patients from the B2 cohort will be conducted in Q3, 2024.

The oral presentation is available here.
The poster presentation is available here.

“PDC*lung01 in combination with anti-PD-1 showed very promising signals suggesting that this combination could offer a clinically meaningful tumor response in stage IV NSCLC patients, along with an interesting mild safety profile,” said Prof Johan Vansteenkiste, emeritus professor in respiratory oncology at KU Leuven in Belgium and chair of the Data and Safety Monitoring Board (DSMB).

“These interim results have real potential; this is a very encouraging step for the company. We are looking forward to sharing the complete set of data when the B2 cohort is complete,” said Dr. Beatrice De Vos, chief medical officer at PDC*line Pharma.

“We are excited to share these very favourable results for our innovative cancer vaccine. The objective response rate of 63.2% and the median progression free survival of 10.9 months along with a mild safety profile are in line with our targets. We’re also encouraged by the evidence of immune response observed in patients, which supports the mechanism of action of PDC*lung01 in relation to clinical activity,” said Eric Halioua, CEO of PDC*line Pharma.

About PDC*lung01

PDC*lung01 is a cell suspension of seven active agents, made of irradiated human Plasmacytoid Dendritic Cells (PDC*line), loaded with HLA-A*02:01-restricted peptides, derived from NY-ESO-1, MAGE-A3, MAGE-A4, Multi-MAGE-A, MUC1, Survivin and Melan-A tumor antigens. PDC*line is a potent professional antigen-presenting cell that is able to prime and boost the patient’s antitumor cytotoxic CD8+ T-cells and is synergistic with anti-Programmed Death-1 (PD-1) treatment.

About PDC*line Pharma’s technology

PDC*line’s biological features provide unique advantages:

· A professional antigen-presenting cell line, much more potent than conventional dendritic cells in priming and expanding antitumor-specific cytotoxic CD8+ T-cells (conventional tumor antigens and neoantigens)
· While allogeneic, PDC*line is not rejected by the host immune system; it can be injected several times to boost the immune response
· Easily produced on a large scale, with a fully mastered and simple manufacturing process (via use of bioreactors with a synthetic medium without growth, differentiation or activation factors)
· Easy to use: after thawing, the same off-the-shelf product is used to treat the whole target population with a cancer type expressing the target antigens
· Very versatile: tumor antigens can be provided by peptide loading, mRNA transfection or retrovirus transduction of PDC*line and the target population can be extended beyond HLA-A2, (currently used as it is expressed by 50% of the Caucasian population), by using other HLAs, either already expressed by PDC*line or added by genetic modification. Moreover, within a few weeks new candidates can be validated for new cancer indications, with ex vivo testing using human Peripheral Blood Mononuclear Cells (PBMC)
· Synergizes with anti-PD-1 to activate antitumor CD8 T-cells

About PDC*line Pharma
Founded in 2014 as a spin-off of the French Blood Bank (EFS), PDC*line Pharma is a Belgian-French clinical-stage biotech company that develops an innovative class of active immunotherapies for cancers, based on a GMP-grade allogeneic therapeutic cell line of Plasmacytoid Dendritic Cells (PDC*line). PDC*line is much more potent than conventional dendritic cell-based vaccines in priming and boosting antitumor antigen-specific cytotoxic T-cells, including the T-cells specific for neoantigens, and is synergistic with checkpoint inhibitors. The technology can potentially be applied to any type of cancer. Following a first-in-human phase I feasibility study in melanoma, PDC*line Pharma focuses on the development of PDC*lung01, a candidate for Non-Small-Cell Lung Cancer (NSCLC) currently in phase I/II trials, and PDC*neo with neoantigens in preclinical development. The company has a staff of 42, with an experienced management team. It has raised more than €62M in equity and non-dilutive funding. In March 2019, PDC*line Pharma granted an exclusive license to the LG Chem Life Sciences company in South Korea and an exclusive option in other Asian countries, for the development and commercialization of the PDC*lung01 cancer vaccine for lung cancer. The total deal is worth $123M, plus tiered royalties on net sales in Asia.

www.pdc-line-pharma.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20240408470952/en/

Website: https://www.pdc-line-pharma.com/ View Korean version of this release Contact PDC*line Pharma
Media and analysts contact
Andrew Lloyd & Associates
Saffiyah Khalique / Juliette Schmitt
UK: +44 1273 952 481
[email protected]
[email protected]
This news is a press release provided by PDC*line Pharma. Korea Newswire follows these editorial guidelines. PDC*line Pharma News ReleasesSubscribeRSS PDC*라인 파마, AACR 2024서 ‘PDC*lung01’ 항암 백신 임상 1/2상 중간 결과 발표 강력한 플랫폼 기반의 면역항암 신약치료제를 개발하는 임상단계 생명공학 회사 PDC*라인 파마(PDC*line Pharma)가 자사의 비소세포폐암 치료 백신 약물인 ‘PDC*lung01’에 대한 임상 1/2상 시험 PDC-LUNG-101(NCT03970746)의 최종 코호트의 중간(interim) 결과를 발표했다. PDC*lung01은 비소세포폐암(Non-Sma... 4월 9일 12:05 PDC*line Pharma and Partners Receive €8.1M From Walloon Region and Wallonia Health Cluster BioWin for Personalized Therapeutic Vaccine Project PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancer, announces today the selection of the PDC*neo+ project for funding by the Walloon region and BioWin, the health cluster for Wallonia. This is the result of a... 1월 18일 15:15 ... More  More News Health Biotechnology Clinical Trials R&D Overseas PDC*line Pharma All News Releases 
배포 분야
인기 기사12.25 23시 기준
리처드슨, 텍사스--(Business Wire / 뉴스와이어)--네트워크의 미래를 구축하는 클라우드 네이티브 네트워크 인프라 제공업체 마베니어(Mavenir)가 옴디아(Omdia)의 새로운 ‘시장 동향: RAN 벤더 2024(Market Landscape: RAN Vendors 2024)’ 보고서에서 새로운 파트너 생태계 부문에서 상위 자리를 차지하면서 새로운 주요...
울산--(뉴스와이어)--울산정보산업진흥원(원장 장병태)이 ‘2023년 SW융합클러스터 2.0 사업’ 및 ‘2023년 지역SW서비스사업화 지원사업’의 일환으로 추진한 지역사회 문제 해결 및 디지털 역량 강화 SW 사례 성과를 발표했다. 에이테크 ‘AI...
서울--(뉴스와이어)--하나은행(은행장 이승열)은 세계적인 금융 전문지인 ‘유로머니(Euromoney)誌’와 미국의 글로벌 금융·경제지인 ‘글로벌 파이낸스(Global Finance)誌’로부터 ‘2024 대한민국 최우수 PB은행상(Best Private Bank in Korea)’과 ‘2024 글로벌 최우수 혁신 PB은행상(Most Innovative Private Bank in the World)’을 각각 수상했다고 밝혔다....
익산--(뉴스와이어)--종합식품기업 하림이 대학생 서포터즈 ‘하림 유니버스’ 3기 참여자를 모집한다. ‘하림 유니버스’ 3기 모집 포스터 ‘하림 유니버스(H-Universe)’는 자기만의 세계관을 만들어 즐기는...
서울--(뉴스와이어)--좋은땅출판사가 ‘시공간 없는 우주의 바깥’을 펴냈다. 이성만 지음, 좋은땅출판사, 344쪽, 2만0000원 이 책은 이성만 저자의 네 번째 책으로, 각종 종교·철학...
TOKYO--(Business Wire / Korea Newswire)--Kura Sushi, Inc. (President: Kunihiko Tanaka; Head Office: Sakai City, Osaka), which operates the conveyor-belt sushi chain “Kura Sushi,” will open “Kura Sushi Global Flagship Store Ginza,” its sixth global...
API
fg
유니콘뉴스는 보도자료 배포 서비스입니다.
여기에 뉴스를 등록하면 언론이 보도하고 널리 배포됩니다.